Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
AgeNot listed
SponsorMayo Clinic

About this trial

This phase IV trial studies whether low dose aspirin can be used to lower inflammation and prevent endometrial cancer in postmenopausal women with changes in the endometrial tissue that are not related to thinning (non-atrophic endometrial changes) and pain. As people age, there is an accumulation of fats, cell death, and inflammation, which causes a surge of pro-cancer-causing events. It is thought that there are several factors involved in the development of endometrial cancer, but that managing the inflammation may address the root cause. Low dose aspirin is aspirin that contains a lower dose than a standard adult tablet. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. Aspirin belongs to the family of drugs called nonsteroidal anti-inflammatory agents. It is also being studied in cancer prevention. Giving low dose aspirin may be an effective way to lower inflammation and prevent endometrial cancer in postmenopausal women with non-atrophic endometrial changes and pain.

Eligibility criteria

Qualifiers

PRE-REGISTRATION: Postmenopausal women

PRE-REGISTRATION: Transvaginal ultrasound

PRE-REGISTRATION: Scheduled endometrial biopsy

PRE-REGISTRATION: Provide risk factor survey

Disqualifiers

PRE-REGISTRATION: Not postmenopausal person born with uterus

PRE-REGISTRATION: Atrophic endometrium

PRE-REGISTRATION: No uterus

PRE-REGISTRATION: Malignancy found

Trial design

Treatments tested in this trial

  • Biospecimen Collection
  • Low-Dose Aspirin
  • Patient Observation
  • Questionnaire Administration
  • Ultrasound Imaging

Treatment groups

25 Participants
are divided into 2 treatment groups

Sponsors and collaborators